NEURIZON THERAPEUTICS LIMITED ASX News

14 November 2024

Neurizon Presents Positive Preclinical Data on NUZ-001

Neurizon Therapeutics presents positive preclinical data for ALS treatment.

Neurizon Therapeutics ALS Biotechnology Neurodegenerative Diseases Stock Market News

Posted on: 14/11/2024

NUZ-001 Reduces Aggregation of Key ALS Disease Target

Neurizon's NUZ-001 shows potential in reducing ALS disease target TDP-43 aggregation.

Neurizon Therapeutics ALS Biotech Drug Development Stock Market News

Posted on: 14/11/2024